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We have recently reported that tyrosine kinase, p56lck
regulates cell motility and nuclear factor B-mediated
secretion of urokinase-type plasminogen activator
(uPA) through tyrosine phosphorylation of IB follow-
ing hypoxia/reoxygenation (Mahabeleshwar, G. H., and
Kundu, G. C. (2003) J. Biol. Chem. 278, 52598–52612).
However, the role of hypoxia/reoxygenation (H/R) on
ERK1/2-mediated uPA secretion and cell motility and
the involvement of p56lck and EGF receptor in these
processes in breast cancer cells is not well defined. We
provide here evidence that H/R induces Lck kinase ac-
tivity and Lck-dependent tyrosine phosphorylation of
EGF receptor in highly invasive (MDA-MB-231) and low
invasive (MCF-7) breast cancer cells. H/R also stimulates
MEK-1 and ERK1/2 phosphorylations, and H/R-induced
phosphorylations were suppressed by the dominant
negative form of Lck (DN Lck, K273R) as well as phar-
macological inhibitors of EGF receptor and Lck indicat-
ing that EGF receptors and Lck are involved in these
processes. Transfection of these cells with wild type Lck
or Lck F505 (Y505F) but not with Lck F394 (Y394F) in-
duced phosphorylations of EGF receptor followed by
MEK-1 and ERK1/2, suggesting that Lck is upstream of
EGF receptor and Tyr-394 of Lck is crucial for these
processes. H/R also induced uPA secretion and cell mo-
tility in these cells. DN Lck and inhibitors of Lck, EGF
receptor, and MEK-1 suppressed H/R-induced uPA se-
cretion and cell motility. To our knowledge, this is the
first report that p56lck in presence of H/R regulates
MEK-1-dependent ERK1/2 phosphorylation and uPA se-
cretion through tyrosine phosphorylation of EGF recep-
tor, and it further demonstrates that all of these signal-
ing molecules ultimately control the motility of breast
cancer cells.
Signal transduction by reactive oxygen species (ROS)1 has
recently become an important target in cellular biology studies
(1, 2). The signaling properties of ROS are largely due to the
reversible oxidation of redox-sensitive target proteins. The gen-
erated ROS act as intracellular second messengers to modulate
signal transduction pathways. ROS play significant roles in
regulating disease- and stress-induced cellular injuries such as
ischemia/reperfusion, UV irradiation, and inflammation (3).
The data also showed that the exposure of cultured cells to
H2O2 resulted in tyrosine phosphorylation of several growth
factor receptors (GFR) in the absence of growth factor (GF)
stimulation (4). Tyrosine phosphorylation of GFR plays impor-
tant role to induce the activation of downstream events similar
to that observed upon GF stimulation.
Lck, a member of the Src family protein tyrosine kinase, is
mostly expressed in T cells and some B cells. We and others
have recently reported that Lck is expressed in breast cancer
tissues and cell lines (5–7). Lck is a typical Src-like tyrosine
kinase, and its activity is regulated by phosphorylation of a
highly conserved tyrosine residue, Tyr-505, located near the
carboxyl terminus (8). In vitro, Lck undergoes autophosphoryl-
ation at Tyr-394 (9), and the extent of phosphorylation at
Tyr-394 correlates with Lck activity and appears to be required
for maximum catalytic activity (10). T-cell antigen receptor
ligation of an Lck-deficient Jurkat mutant, J.CaM1, failed to
induce tyrosine phosphorylation and activation of p42MAPK
upon anti-CD3 or monoclonal anti-T-cell antigen receptor 
antibody treatment. The same stimuli activated p42MAPK in
J.CaM1 cells transfected with p56lck, demonstrating that Lck
plays an important role in MAP kinase activation (11).
Epidermal growth factor receptor (EGFR) belongs to the
erbB growth factor receptor family. EGF and its receptor are
frequently up-regulated in many human cancers. It has also
been described that c-Src catalytic activity is required for inte-
grin-EGF receptor macromolecular complex formation and
EGF receptor phosphorylation. Similarly, when cells were ex-
posed to the Src kinase inhibitor pp1, tyrosine phosphorylation
of EGF receptor induced by integrin-mediated adhesion was
strongly reduced. Simultaneously, overexpression of a kinase
negative form of c-Src strongly reduced integrin-dependent
EGF receptor phosphorylation, suggesting that c-Src is up-
stream of EGF receptor (12). The EGF receptor has been shown
to be instrumental in the activation of MAPK pathways and
cell motility in different cell types (13, 14). Previous results
indicated that extracellular-regulated kinase (ERK1/2), a
member of the MAPK family, plays an important role in EGF
receptor-mediated cell signaling. Inhibition of ERK1/2 by the
MEK-1 inhibitor, PD98059, resulted in the significant inhibi-
tion of the basal cell migration (15). ERK1/2 also plays a key
role in the regulation of AP-1 as its activation leads to the
induction of c-Fos, which may associate with c-Jun to form a
second AP-1 heterodimeric complex for the regulation of uPA
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expression (16). However, the molecular mechanism by which
p56lck in the presence of H/R regulates EGF receptor phospho-
rylation and ERK1/2 activation in human breast cancer cells is
not well defined.
uPA is involved in cell adhesion, cell motility, tumor growth,
and metastasis. It is also regulated at transcriptional level by
multiple transcription factors. AP-1 transcription factor duplex
plays a major role in the control of inducible uPA expression
through binding of enhancer regions in the promoter of the uPA
gene (17). The signaling pathways by which p56lck in the pres-
ence of H/R controls the uPA secretion and cell motility through
the activation of MEK-1/ERK1/2 pathways in breast cancer
cells are not clearly understood.
In this study, we investigate the involvement of p56lck in the
redox-regulated activations of MEK-1 and ERK1/2 and secre-
tion of uPA through the tyrosine phosphorylation of EGF re-
ceptor following H/R in MCF-7 and MDA-MB-231 cells. We
demonstrate that H/R induced p56lck kinase activity, which
ultimately phosphorylates EGF receptor and activates ERK1/2
through the MEK-1-dependent pathway. These lead to the
induction of uPA secretion and cell motility, which is prereq-
uisite for proteolytic degradation, extracellular matrix inva-
sion, and distant metastasis.
EXPERIMENTAL PROCEDURES
Materials—The rabbit polyclonal anti-p56lck, anti-actin, anti-EGF
receptor, anti-ERK1/2, anti-MEK-1, anti-phospho-MEK-1 and mouse
monoclonal anti-phosphotyrosine, and anti-phospho-ERK1/2 antibodies
were purchased from Santa Cruz Biotechnology. The mouse monoclonal
anti-uPA antibody was obtained from Oncogene. pp2 (4-amino-5-(4-
chlorophenyl)-7-(t-butyl) pyrazolo [3,4-d] pyrimidine), emodin (6-meth-
yl-1,3,8-trihydroxyanthraquinone), aminogenistein (4-amino-6-hy-
droxyflavone), damnacanthal (3-hydroxy-1-methoxy anthraquinone-2-
aldehyde), AG-99 (-cyano-(3,4-dihydroxy) cinnamide), PD153035
[4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline], U0126 (1,4-dia-
mino-2,3-dicyano-1,4-bis(2-aminophenylthio) butadiene), and PD98059
(2-amino-3-methoxyflavone) were purchased from Calbiochem. Rabbit
muscle enolase was from ICN. [-32P] ATP was purchased from the
Board of Radiation and Isotope Technology (Hyderabad, India).
pTRACER-A vector and LipofectAMINE Plus reagent were purchased
from Invitrogen. Boyden type cell migration chambers were from Corn-
ing. All other chemicals were analytical grade.
Cell Culture—The MDA-MB-231 and MCF-7 cells were purchased
from ATCC (Manassas, VA). Both MDA-MB-231 and MCF-7 cells were
cultured in Dulbecco’s modified Eagle’s medium. The media were sup-
plemented with 10% fetal calf serum, 100 units/ml penicillin, 100 g/ml
streptomycin, and 2 mM glutamine in a humidified atmosphere of 5%
CO2 and 95% air at 37 °C.
Hypoxic Cultures—The MCF-7 and MDA-MB-231 cells grown to 50–
70% confluency were made hypoxic in evacuation chambers by inter-
mittent application of vacuum and sparging with 95% N2, 5% CO2. Cells
were analyzed at this point or maintained under hypoxic conditions in
the presence of 100 mM dithionate (an oxygen scavenger) at 37 °C for
0–3 h. These cells were reoxygenated for the indicated periods by
replacing the medium with fresh medium and incubating the cultures
in a humidified atmosphere of 5% CO2 and 95% air at 37 °C.
Plasmids and DNA Transfection—The wild type Lck, mutant Lck
F394 (Y394F), and Lck F505 (Y505F) cDNAs in an expression vector
(pCEP4) were generous gifts from Dr. B. M. Sefton (The Salk Institute,
La Jolla, CA). The dominant negative form of Lck (DN Lck, K273R) in
pcDNA3 was a kind gift from Dr. D. R. Branch (Canadian Blood Ser-
vices, Toronto, Ontario). Both MCF-7 and MDA-MB-231 cells were
transiently transfected with Lck cDNA using LipofectAMINE Plus ac-
cording to the methods as described earlier (6). These transfected cells
were used for Lck kinase activity, detection of phosphorylations of Lck,
EGF receptor, MEK-1, and ERK1/2, and uPA secretion by Western blot
analysis and cell migration.
The transfection efficiency was assessed as described previously (18).
Briefly, both of these cells were cotransfected with wild type or mutant
Lck cDNA and pTRACER-A vector (Invitrogen) containing green fluo-
rescent protein in the presence of LipofectAMINE Plus. The cells were
allowed to grow for 24 h and then analyzed under fluorescence micros-
copy. Transfection efficiency was assessed by dividing the number of
green fluorescent cells by the total cell number in the same randomly
chosen fields in each transfection.
Immunoprecipitation and Western Blot Analysis—To examine
whether EGF receptor is involved in H/R-induced tyrosine phosphoryl-
ation of p56lck, both MCF-7 and MDA-MB-231 cells were pretreated
with different concentrations of EGF receptor inhibitors (0–35 pM
PD153035 or 0–15 M AG-99) and then induced by H/R for 90 min. The
cells were lysed in lysis buffer (1% Triton X-100 solution containing 1
mM phenylmethylsulfonyl fluoride, 20 g/ml leupeptin, and 2 mM
EDTA). Equal amounts of total proteins in lysates were immunopre-
cipitated with rabbit polyclonal anti-Lck antibody. The immunoprecipi-
tated samples were analyzed by Western blot using mouse monoclonal
anti-phosphotyrosine antibody. The same blots were reprobed with
rabbit polyclonal anti-Lck antibody.
To delineate whether H/R plays any role in the regulation of EGF
receptor phosphorylation, both of these cells were induced by H/R for
0–120 and 0–135 min, respectively. An equal amount of total proteins
from the cell lysates were immunoprecipitated with rabbit polyclonal
anti-EGFR antibody. The immunoprecipitated samples were immuno-
blotted with anti-phosphotyrosine antibody. The same blots were rep-
robed with anti-EGFR antibody. To check whether Lck plays any role in
regulation of EGF receptor phosphorylation, both of these cells were
individually treated with various concentrations of Lck inhibitors (0–16
M emodin, 0–4 nM pp2, 0–2 M aminogenistein, and 0–0.8 M dam-
nacanthal) for 24 h and then induced by H/R for 75 min in MCF-7 cells
and for 90 min in MDA-MB-231 cells.
In separate experiments, cells were individually transfected with DN
Lck and then induced by H/R. The dominant negative activity of Lck
was also verified by Yousefi et al. (19). In other experiments, cells were
transfected with wild type Lck, Lck F394, and Lck F505, and wild type
Lck transfected cells were treated with maximum doses of Lck inhibi-
tors (16 M emodin, 4 nM pp2, 2 M aminogenistein, and 0.8 M dam-
nacanthal) and then induced by H/R as described above. Cell lysates
were immunoprecipitated with anti-EGFR antibody and immuno-
blotted with anti-phosphotyrosine antibody as described above. The
same blots were reprobed with anti-EGFR antibody.
To examine whether H/R induces the phosphorylation of MEK-1 and
whether H/R-induced MEK-1 phosphorylation is regulated by Lck or
EGF receptor, MDA-MB-231 cells were transfected with DN Lck, wild
type Lck, mutant Lck F394, or Lck F505 and wild type Lck transfected
cells were treated with Lck inhibitors (16 M emodin, 4 nM pp2, 2 M
aminogenistein, and 0.8 M damnacanthal) for 24 h and then induced
by H/R for 90 min. In other experiments, cells were treated with various
concentrations of EGF receptor inhibitors (0–35 pM PD153035 and
0–15 M AG-99) and then induced by H/R as described above. Equal
amount of total proteins from treated or transfected cell lysates were
analyzed by Western blot using rabbit anti-phospho-MEK-1 antibody.
The same blots were reprobed with rabbit anti-MEK-1 antibody.
To check whether H/R regulates the ERK1/2 phosphorylation and
H/R-induced ERK1/2 phosphorylation is governed by Lck, EGF recep-
tor, and MEK-1, MDA-MB-231 cells were transfected with DN Lck, wild
type Lck, mutant Lck F394, or Lck F505, and wild type Lck transfected
cells were treated with Lck inhibitors or EGF receptor inhibitors or
MEK-1 inhibitors as described above. These cells were then induced
with H/R, and cell lysates were immunoblotted with mouse monoclonal
anti-phospho-ERK1/2 antibody. The same blots were reprobed with
rabbit anti-ERK1/2 antibody.
To investigate the roles of Lck, EGF receptor, and MEK-1 on H/R-
induced uPA secretion, MDA-MB-231 cells were transfected with DN
Lck, wild type Lck, mutant Lck F394 or Lck F505, and wild type Lck
transfected cells were treated with maximum concentrations of inhibi-
tors of Lck, EGF receptor, or MEK-1 as described above and induced by
H/R for 24 h. Cell lysates were analyzed by Western blot using mouse
monoclonal anti-uPA antibody. As loading controls, the same blots were
reprobed with rabbit polyclonal anti-actin antibody.
Immunoprecipitation and in Vitro Kinase Assay—To delineate the
effect of H/R on Lck kinase activity, both of these cells were either
transiently transfected with wild type Lck, mutant Lck F394, or Lck
F505 or treated with different concentrations of EGF receptor inhibitors
(0–35 pM PD153035 or 0–15 M AG-99) and then induced by H/R for 90
min. Cell lysates containing an equal amount of total proteins were
immunoprecipitated with rabbit polyclonal anti-Lck antibody. The im-
munoprecipitated samples were used for Lck kinase assay using acid
denatured enolase as substrate as described earlier (10).
To examine whether H/R regulates the EGF receptor kinase activity
and to check the specificity of Lck inhibitors in H/R-induced EGF
receptor activation, the EGF receptor kinase assays were performed as
described (20). Briefly, cells were induced by H/R, and the lysates were
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immunoprecipitated with anti-EGFR antibody. The immunocomplex
was incubated with Lck inhibitors and used for EGF receptor kinase
assay.
Cell Migration Assay—The migration assay was conducted using a
Transwell cell culture chamber according to the standard procedure as
described previously (21, 22). Briefly, both MCF-7 and MDA-MB-231
cells were exposed with H/R, and a cell suspension (5  105 cells/well)
was added to the upper chamber of the polycarbonate membrane filter.
The lower chamber was filled with fibroblast-conditioned medium,
which acted as chemoattractant. In separate experiments, MDA-MB-
231 cells were pretreated with Lck inhibitors (0–16 M emodin, 0–4 nM
pp2, 0–2 M aminogenistein, and 0–0.8 M damnacanthal) and induced
by H/R for 24 h. In other experiments, both MCF-7 and MDA-MB-231
cells were individually transfected with DN Lck, wild type Lck, mutant
Lck F394 or Lck F505, and wild type Lck transfected cells were treated
with inhibitors of Lck, EGF receptor or MEK-1, or anti-uPA antibody as
described earlier and then induced by H/R for 24 h. After treatment or
transfection, cells were added to the upper chamber of the polycarbon-
ate membrane filter and incubated at 37 °C for 16 h. The non-migrated
cells on the upper side of the filter were scraped, and the filter was
washed. The migrated cells in the reverse side of the filter were fixed
with methanol and stained with Giemsa. The migrated cells on the
filter were counted under an inverted microscope (Olympus). The ex-
periments were repeated in triplicate. Preimmune IgG served as a
non-specific control.
RESULTS
H/R Induces Lck Phosphorylation and Its Kinase Activity—
We have investigated the effect of H/R on Lck-dependent MEK-
1/ERK1/2-mediated uPA secretion through tyrosine phospho-
rylation of EGF receptor in breast cancer cells. Accordingly, we
first examined whether H/R is able to induce tyrosine phospho-
rylation of Lck and its kinase activity in low invasive (MCF-7)
and highly invasive (MDA-MB-231) breast cancer cells. Both of
these cells were transiently transfected with wild type Lck,
mutant Lck F394, and Lck F505 and induced with H/R for 90
min. These transfected cells were immunoprecipitated with
anti-Lck antibody, and immunoprecipitated samples were used
for kinase assay using enolase as substrate. The data revealed
that H/R induced Lck kinase activity in MCF-7 (Fig. 1A, lane 2)
and MDA-MB-231 (Fig. 1B, lane 2) cells as compared with cells
grown under normoxic conditions (lane 1). Both wild type Lck
and mutant Lck F505 enhanced the phosphorylation of enolase
in MCF-7 (Fig. 1A, lanes 3 and 5) and MDA-MB-231 (Fig. 1B,
lanes 3 and 5) cells as compared with cells transfected with Lck
F394 (Fig. 1, A and B, lane 4). These results indicated that H/R
induced the Lck kinase activity in both of these cells and also
suggested that Tyr-394 of Lck is important for this process. To
delineate whether p56lck is located upstream of EGF receptor
in ROS-mediated signaling pathway, both of these cells were
pretreated with EGF receptor inhibitors, induced by H/R, and
immunoprecipitated with anti-Lck antibody, and immunopre-
cipitated samples were used for Lck kinase assay. The data
indicated that EGF receptor inhibitors have no effect on Lck
kinase activity in both MCF-7 and MDA-MB-231 cells (Fig. 1, C
and D, lanes 1–4), suggesting that Lck is located upstream of
EGF receptor in these pathways.
To delineate whether EGF receptor plays any significant role
in H/R-induced tyrosine phosphorylation of Lck, both of these
cells were treated with EGF receptor inhibitors and then in-
duced by H/R. Cell lysates were immunoprecipitated with anti-
Lck antibody and immunoblotted with anti-phosphotyrosine
antibody (Fig. 1, E and F, upper panels, lanes 1–8), and the
same blots were reprobed with anti-Lck antibody as loading
FIG. 1. As shown in A and B, H/R induces Lck kinase activity in low invasive (MCF-7) and highly invasive (MDA-MB-231) breast cancer cells.
Both MCF-7 (A) and MDA-MB-231 (B) cells were individually transfected with wild type (WT) or mutant Lck (F394 or F505) and then induced by
H/R for 90 min. Cell lysates were immunoprecipitated with rabbit polyclonal anti-Lck antibody. The immunoprecipitated samples were used for
Lck kinase assay using rabbit muscle enolase as substrate. Lane 1, without H/R; lane 2, induced by H/R; lane 3, transfection with wild type Lck
and induced by H/R; lane 4, transfection with Lck F394 and induced by H/R; and lane 5, transfection with Lck F505 and induced by H/R. As shown
in C and D, H/R-induced Lck kinase activity is independent of EGF receptor activation. MCF-7 (C) and MDA-MB-231 (D) cells were pretreated with
EGF receptor inhibitors and then induced by H/R as described. The cell lysates were immunoprecipitated with anti-Lck antibody and used for Lck
kinase assay. Lane 1, without H/R; lane 2, induced by H/R; lane 3, treated with PD153035 and induced by H/R; and lane 4, treated with AG-99 and
induced by H/R. As shown in E and F, H/R-induced tyrosine phosphorylation of Lck is independent of EGF receptor activation. MCF-7 (E) and
MDA-MB-231 (F) cells were pretreated with various concentrations of EGF receptor inhibitors and then induced by H/R. The cell lysates were
immunoprecipitated with anti-Lck antibody, and the immunoprecipitated samples were analyzed by Western blot using anti-phosphotyrosine
antibody (E and F, upper panels, lanes 1–8). The same blots were reprobed with anti-Lck antibody (E and F, lower panels, lanes 1–8).
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control (Fig. 1, E and F, lower panels, lanes 1–8). The inhibitors
of EGF receptor have no effect on H/R-induced tyrosine phos-
phorylation of Lck. These data further confirmed that Lck is
upstream of EGF receptor in these pathways. All of these
bands were quantified by densitometric analysis, and the val-
ues of -fold changes are calculated.
To examine the transfection efficiency, both MCF-7 and
MDA-MB-231 cells were cotransfected with Lck and
pTRACER-A vector (Invitrogen) in the presence of Lipo-
fectAMINE Plus. The cells were analyzed under fluorescence
microscopy. The transfection efficiency was quantified by di-
viding the number of green fluorescent cells by the total cell
number in the same randomly chosen fields in each transfec-
tion, and a high level of transfection efficiency was observed in
MCF-7 (82%) and MDA-MB-231 (78%) cells (data not shown).
H/R Enhances EGF Receptor Phosphorylation and Its Ki-
nase Activity—We have examined the effect of H/R on phospho-
rylation of EGF receptor in breast cancer cells. Accordingly,
MCF-7 cells were stimulated with H/R for 0–120 min, and
MDA-MB-231 cells were induced by H/R for 0–135 min. The
cell lysates were immunoprecipitated with rabbit polyclonal
anti-EGF receptor antibody, and the immunocomplex was an-
alyzed by Western blot using anti-phosphotyrosine antibody.
The data showed that H/R induced EGF receptor phosphoryl-
ation in MCF-7 (Fig. 2A, upper panel, lanes 1–8) and in MDA-
MB-231 (Fig. 2B, upper panel, lanes 1–9) cells. The same blots
were reprobed with anti-EGF receptor antibody as loading
control (Fig. 2, A and B, lower panels). The bands were quan-
tified densitometrically, and the values of -fold changes are
calculated.
To examine the effect of H/R on EGF receptor kinase activity
and to check the specificity of Lck inhibitors on this activity,
both of these cells were induced by H/R and immunoprecipi-
tated with anti-EGF receptor antibody. The immunoprecipi-
tated samples were treated in the absence or presence of Lck
inhibitors and used for kinase assay. The results showed that
H/R induced EGF receptor kinase activity and Lck inhibitors
have no inhibitory effect on H/R-induced kinase activity of EGF
receptor in both of these cells (Fig. 2, C and D, lanes 1–6).
p56lck Is Involved in H/R-induced EGF Receptor Phospho-
rylation—To delineate the role of Lck in H/R-induced EGF
receptor phosphorylation, both of these cells were pretreated
with different concentrations of Lck-specific inhibitors and
then induced by H/R. Cell lysates were immunoprecipitated
with anti-EGF receptor antibody and immunoblotted with anti-
phosphotyrosine antibody. The data showed that H/R-induced
tyrosine phosphorylation of EGF receptor was dramatically
suppressed by Lck inhibitors in a dose-dependent manner in
MCF-7 (Fig. 3A, upper panel, lanes 1–14) and MDA-MB-231
(Fig. 3B, upper panel, lanes 1–14) cells. The same blots were
reprobed with anti-EGF receptor antibody as loading control
(Fig. 3, A and B, lower panels, lanes 1–14). These results clearly
suggested that Lck plays a crucial role in H/R-induced EGF
receptor phosphorylation.
To further confirm whether Lck plays any role in H/R-in-
duced EGF receptor tyrosine phosphorylation, both of these
cells were transfected with DN Lck and induced by H/R. Cell
lysates were immunoprecipitated with anti-EGF receptor an-
tibody and immunoblotted with anti-phosphotyrosine anti-
body. The data indicated that DN Lck suppressed the H/R-
induced tyrosine phosphorylation of EGF receptor in MCF-7
(Fig. 3C, upper panel, lanes 1–3) and MDA-MB-231 (Fig. 3D,
upper panel, lanes 1–3) cells. The same blots were reprobed
with anti-EGF receptor antibody as loading control (Fig. 3, C
and D, lower panels, lanes 1–3). In separate experiments, both
of these cells were transiently transfected with wild type Lck,
mutant Lck F394, or Lck F505, and wild type Lck transfected
cells were treated with maximum doses of Lck inhibitors and
induced by H/R. The data showed that both wild type Lck and
Lck F505 enhanced the H/R-induced tyrosine phosphorylation
of EGF receptor in MCF-7 (Fig. 3E, upper panel, lanes 3 and 5)
and MDA-MB-231 (Fig. 3F, upper panel, lanes 3 and 5) cells as
compared with cells transfected with Lck F394 (Fig. 3, E and F,
upper panels, lane 4) or induced by H/R alone (Fig. 3, E and F,
upper panels, lane 2). As expected, no phospho-specific band
was detected in cells grown under normoxic conditions (Fig. 3,
E and F, upper panels, lane 1). Lck inhibitors drastically sup-
pressed the H/R-induced EGF receptor phosphorylation in wild
FIG. 2. As shown in A and B, H/R enhances EGF receptor phosphorylation. MCF-7 (A) and MDA-MB-231 (B) cells were induced by H/R, cell
lysates were immunoprecipitated with anti-EGF receptor antibody, and the immunocomplexes were immunoblotted with anti-phosphotyrosine
antibody. Note that H/R induced tyrosine phosphorylation of EGF receptor in MCF-7 (A, upper panel, lanes 1–8) and MDA-MB-231 (B, upper panel,
lanes 1–9) cells. The same blots were reprobed with anti-EGF receptor antibody as loading control (A, lower panel, lanes 1–8; B, lower panel, lanes
1–9). C and D, effects of Lck inhibitors on H/R-induced EGF receptor kinase activity. MCF-7 (C) and MDA-MB-231 (D) cells were induced by H/R,
and cell lysates were immunoprecipitated with anti-EGF receptor antibody. The immunocomplex was incubated in the absence or presence of Lck
inhibitors, and a kinase assay was performed. Lck inhibitors have no effect on H/R-induced EGF receptor kinase activity in MCF-7 (C, lanes 1–6)
and MDA-MB-231 (D, lanes 1–6) cells. All of these bands were analyzed densitometrically, and -fold changes are calculated. The results shown here
represent three experiments exhibiting similar effects.
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type Lck transfected cells (Fig. 3, E and F, upper panels, lanes
6–9). The expression of non-phospho-EGF receptor was shown
as loading control (Fig. 3, E and F, lower panels, lanes 1–9).
This data clearly suggested that Lck is directly involved in
H/R-induced EGF receptor phosphorylation and Tyr-394 of Lck
plays a critical role in this phosphorylation process. All of these
bands were quantified by densitometric analysis and the val-
ues of -fold changes are calculated.
H/R-induced Breast Cancer Cell Migration Is p56lck-depend-
ent—In this study, we have demonstrated that p56lck is in-
volved in EGF receptor phosphorylation upon H/R induction.
Therefore, we sought to determine whether p56lck has any role
in breast cancer cell migration in the presence of H/R. MDA-
MB-231 cells were pretreated with different concentrations of
Lck inhibitors and then induced by H/R. These treated cells
were used for a cell migration assay. The data indicated that
MDA-MB-231 cells exposed with H/R showed higher migration
(695%) than cells grown under normoxic conditions (100%)
(Fig. 4, A and B). Pretreatment of MDA-MB-231 cells with
emodin (398–132%), pp2 (320–109%), aminogenistein (415–
134%), or damnacanthal (308–119%) showed drastic suppres-
sion of H/R-induced cell migration (Fig. 4, A and B). Similar
results were obtained when MCF-7 cells were used for these
studies (data not shown). In other experiments, both MCF-7
and MDA-MB-231 cells were individually transfected with wild
type Lck, DN Lck (K273R), Lck F394, or Lck F505, and wild
type Lck transfected cells were treated with maximum doses of
Lck inhibitors and induced by H/R. The high level of transfec-
tion efficiency was observed in both MCF-7 (82%) and MDA-
MB-231 (78%) cells. These cells were used for migration assay,
and both wild type Lck (880% in MCF-7 and 1076% in MDA-
MB-231) and Lck F505 (872% in MCF-7 and 1072% in MDA-
MB-231) transfected cells showed maximum migration as com-
pared with Lck F394 transfected cells (560% in MCF-7 and
700% in MDA-MB-231) (Fig. 4, C and D). H/R-induced migra-
tion was suppressed when cells were transfected with DN Lck
(K273R) in MCF-7 (Fig. 4C) and MDA-MB-231 (Fig. 4D) cells.
Lck inhibitors dramatically blocked the H/R-induced cell mi-
FIG. 3. p56lck is involved in H/R-induced EGF receptor phosphorylation. As shown in A and B, MCF-7 (A) and MDA-MB-231 (B) cells
were individually pretreated with various concentrations of Lck-specific inhibitors and then induced by H/R. Cell lysates were immunoprecipitated
with rabbit anti-EGF receptor antibody, and immunoprecipitated samples were analyzed by Western blot using anti-phosphotyrosine antibody.
The same blots were reprobed with anti-EGF receptor antibody. Note that H/R-induced tyrosine phosphorylation of EGF receptor was inhibited
by Lck inhibitors in a dose-dependent manner (A and B, upper panels, lanes 1–14). The expression of non-phospho-EGF receptor was shown as
loading control (A and B, lower panels, lanes 1–14). As shown in C–F, MCF-7 (C and E) and MDA-MB-231 (D and F) cells were transiently
transfected with wild type (WT) Lck, DN Lck, mutant Lck F394, and Lck F505, and wild type Lck transfected cells were treated with Lck inhibitors.
All of these transfected cells were induced by H/R, and cell lysates were immunoprecipitated with anti-EGF receptor antibody and immunoblotted
with anti-phosphotyrosine antibody. Note that cells transfected with DN Lck suppressed the H/R-induced EGF receptor phosphorylation in MCF-7
(C, upper panel, lanes 1–3) and in MDA-MB-231 (D, upper panel, lanes 1–3) cells. MCF-7 (E) or MDA-MB-231 (F) cells transfected with wild type
Lck or Lck F505 but not with Lck F394 induced the EGF receptor phosphorylation in the presence of H/R (E and F, upper panels, lanes 2–5).
Lck-induced EGF receptor phosphorylation was completely inhibited by Lck inhibitors in the presence of H/R in these cells (E and F, upper panels,
lanes 3 and 6–9). The same blots were reprobed with anti-EGF receptor antibody as loading control (C–F, lower panels). All of these bands were
quantified by densitometric analysis, and the values of -fold changes are calculated. The results shown here represent three experiments exhibiting
similar effects.
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gration in wild type Lck-transfected MCF-7 and MDA-MB-231
cells (Fig. 4, C and D). These results suggested that H/R in-
duced Lck-mediated breast cancer cell migration and Tyr-394
of Lck plays a crucial role in this process. The data are ex-
pressed as the means  S.E. of three determinations. The
values were also analyzed by Student’s t test (p  0.002).
H/R-induced p56lck and EGF Receptor-dependent MEK-1
and ERK1/2 Phosphorylations—To examine the effect of H/R
on phosphorylations of MEK-1 and ERK1/2 and whether Lck
and EGF receptors are involved in these processes, MDA-MB-
231 cells were transfected with wild type Lck, DN Lck (K273R),
mutant Lck F394, or Lck F505, and wild type Lck transfected
cells were treated with various Lck inhibitors and then induced
by H/R. In other experiments, cells were either treated with
EGF receptor inhibitors or transfected with wild type Lck, DN
Lck (K273R), mutant Lck F394, or Lck F505, and wild type Lck
transfected cells were treated with EGF receptor inhibitors or
MEK-1 inhibitors and then induced by H/R. The transfection
efficiency was monitored, and a high level of transfection effi-
ciency was detected in both MCF-7 (82%) and MDA-MB-231
(78%) cells. Cell lysates were analyzed by Western blot using
anti-phospho-MEK-1 or anti-phospho-ERK1/2 antibody. The
data indicated that both wild type Lck and Lck F505 enhanced
the H/R-induced MEK-1 phosphorylation as compared with
Lck F394 transfected cells (Fig. 5A, upper panel, lanes 2–5).
H/R-induced MEK-1 phosphorylation is reduced when cells
were transfected with DN Lck (lane 6). A low level of phospho-
rylated MEK-1 was detected in cells grown under normoxic
FIG. 4. Role of p56lck in H/R-induced cell migration. As shown in A and B, MDA-MB-231 cells were pretreated with various concentrations
of Lck-specific inhibitors and then induced by H/R. These treated cells were used for cell migration assay as described under “Experimental
Procedures.” The number of cells migrated under normoxic conditions was considered as 100%. H/R induced the cell migration, and Lck inhibitors
suppressed the H/R-induced cell migration in a dose-dependent manner (A and B). As shown in C and D, MCF-7 (C) and MDA-MB-231 (D) cells
were individually transfected with wild type (WT) Lck, DN Lck, mutant Lck F394, or Lck F505, and wild type Lck transfected cells were treated
with maximum doses of Lck inhibitors, induced by H/R, and used for migration assay. Both wild type Lck and Lck F505 transfected cells showed
maximum cell migration as compared with Lck F394 transfected cells or cells induced by H/R alone. DN Lck transfected cells reduced the
H/R-induced migration. Lck inhibitors suppressed H/R-induced cell migration in wild type Lck transfected cells. The results are expressed as the
means  S.E. of three determinations. The values were also analyzed by Student’s t test (p  0.002).
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conditions (lane 1). Lck inhibitors drastically inhibited the
H/R-induced MEK-1 phosphorylation in wild type Lck trans-
fected cells (lanes 7–10). The data also showed that EGF recep-
tor inhibitors dose-dependently blocked the H/R-induced
MEK-1 phosphorylation (Fig. 5B, upper panel, lanes 1–8). Sim-
ilarly, wild type Lck or Lck F505 enhanced the H/R-induced
ERK1/2 phosphorylation as compared with Lck F394 trans-
fected cells or cells induced by H/R alone (Fig. 5C, upper panel,
lanes 2–5). Lck inhibitors dramatically suppressed the H/R-
induced ERK1/2 phosphorylation in wild type Lck transfected
cells (lanes 6–9). DN Lck blocked the H/R-induced ERK1/2
phosphorylation (Fig. 5D, upper panel, lanes 1–3). The results
also indicated that inhibitors of EGF receptor or MEK-1 sup-
pressed the H/R-induced ERK1/2 phosphorylation in wild type
Lck transfected cells (lanes 1–7). The same blots were reprobed
with either anti-MEK-1 or anti-ERK1/2 antibody as loading
control (Fig. 5, A–E, lower panels). These results suggested that
H/R induces MEK-1 and ERK1/2 phosphorylations through Lck
and EGF receptor-mediated pathways. The same results were
obtained in MCF-7 cells (data not shown).
H/R Induces uPA Secretion through p56lck-dependent EGF
Receptor and MEK-1-mediated Pathways—To delineate the
roles of Lck, EGF receptor, and ERK in H/R-induced uPA
secretion, MDA-MB-231 cells were transfected with wild type
Lck, DN Lck, mutant Lck F394, or Lck F505, and wild type Lck
transfected cells were treated with inhibitors of Lck, MEK-1,
and EGF receptor and then induced by H/R for 24 h. The high
level of transfection efficiency was observed in both MCF-7 and
MDA-MB-231 cells. Cell lysates were analyzed by Western blot
using mouse monoclonal anti-uPA antibody. The data indicated
that both wild type Lck or Lck F505 transfected cells showed a
higher level of uPA secretion as compared with H/R-induced or
Lck F394 transfected cells (Fig. 6A, upper panel, lanes 2–5).
Lck-specific inhibitors blocked the H/R-induced uPA secretion
in wild type Lck transfected cells (lanes 6–9). DN Lck sup-
pressed the H/R-induced uPA secretion (Fig. 6B, upper panel,
lanes 2 and 3). The data also revealed that inhibitors of EGF
receptor or MEK-1 suppressed the H/R-induced uPA secretion
in wild type Lck transfected cells (Fig. 6C, upper panel, lanes
2–7). A low level of uPA was detected in cells grown under
normoxic conditions (Fig. 6, A–C, upper panels, lane 1). All of
these blots were reprobed with anti-actin antibody as loading
controls (Fig. 6, A–C, lower panels) and quantified by densito-
metric analysis. The values were normalized with respect to
actin, and -fold changes were calculated. These results demon-
strated that H/R induced uPA secretion through Lck-depend-
ent EGF receptor and ERK-mediated pathways. Similar re-
sults were obtained in MCF-7 cells (data not shown).
H/R Stimulates Lck-dependent EGF Receptor, MEK-1, and
uPA-mediated Cell Migration—We and others have recently
FIG. 5. Roles of p56lck and EGF receptor on H/R-induced MEK-1 phosphorylation (Ser-222 and -226). As shown in A, MDA-MB-231 cells
were transiently transfected with wild type (WT) Lck, DN Lck, mutant Lck F394, or Lck F505, and wild type Lck transfected cells were treated
with maximum doses of Lck inhibitors and induced by H/R. The levels of phospho-MEK-1 (p-MEK-1) and MEK-1 were detected by Western blot
analysis. Cells transfected with wild type Lck or Lck F505 showed maximum phosphorylation of MEK-1 as compared with cells transfected with
Lck F394 or induced by H/R alone (A, upper panel, lanes 1–5). DN Lck inhibited the H/R-induced MEK-1 phosphorylation (lane 6). Lck inhibitors
drastically inhibited H/R-induced MEK-1 phosphorylation in wild type Lck-transfected cells (lanes 7–10). As shown in B, MDA-MB-231 cells were
treated with various concentrations of EGF receptor inhibitors and induced by H/R, and cell lysates were immunoblotted with anti-phospho-MEK-1
antibody. The results indicated that EGF receptor inhibitors suppressed the H/R-induced MEK-1 phosphorylation in these cells (B, upper panel,
lanes 1–8). The same blots were reprobed with anti-MEK antibody as loading control (A and B, lower panel). As shown in C–E, H/R-induced
p56lck-dependent ERK1/2 phosphorylation occurred through EGF receptor and MEK-1 mediated pathways. MDA-MB-231 cells were individually
transfected with wild type Lck, DN Lck, mutant Lck F394, or Lck F505 and then induced by H/R. In separate experiments, wild type Lck
transfected cells were treated with maximum doses of inhibitors of Lck, EGF receptor, or MEK-1 and induced by H/R. The level of phospho-ERK1/2
(p-ERK-1/2) was detected by Western blot using anti-phospho-ERK1/2 antibody. The phosphorylation of ERK1/2 was higher in cells transfected
with wild type Lck or Lck F505 as compared with Lck F394 transfected cells or cells induced by H/R alone (C, upper panel, lanes 1–5). Lck inhibitors
dramatically blocked the H/R-induced ERK phosphorylation of wild type Lck transfected cells (lanes 6–9). DN Lck suppressed the H/R-induced
ERK1/2 phosphorylation (D, upper panel, lanes 1–3). Inhibitors of EGF receptor and MEK-1 suppressed the H/R-induced ERK1/2 phosphorylation
in wild type Lck transfected cells (E, upper panel, lanes 1–7). As loading control, all of these blots were reprobed with anti-ERK1/2 antibody (C–E,
lower panels). All of these bands were quantified by densitometric analysis, and the values of -fold changes are calculated. The data shown here
represent three experiments exhibiting similar effects.
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demonstrated that uPA plays significant role in regulation of
breast cancer cell migration (6, 23, 24). However, in this study,
we have shown that Lck regulates the EGF receptor-mediated
ERK-dependent uPA secretion in breast cancer cells in the
presence of H/R. Therefore, we sought to determine whether
EGF receptor and MEK-1 play any roles in Lck-mediated
breast cancer cell migration in the presence of H/R. Accord-
ingly, both MCF-7 (Fig. 6D) and MDA-MB-231 (Fig. 6E) cells
were transfected with wild type Lck, Lck F394, or Lck F505,
and wild type Lck transfected cells were treated with inhibitors
of EGF receptor or MEK-1 and induced by H/R. The high level
of transfection efficiency was observed in both of these cells.
These cells were used for cell migration assay. The data indi-
cated that both wild type Lck (880% in MCF-7 and 1076% in
MDA-MB-231) and Lck F505 (872% in MCF-7 and 1072% in
MDA-MB-231) transfected cells showed maximum migration
as compared with Lck F394 transfected cells (560% in MCF-7
and 700% in MDA-MB-231) or cells induced by H/R alone (Fig.
6, D and E). The inhibitors of EGF receptor, PD153035 (65% in
MCF-7 and 68% in MDA-MB-231 cells), or AG-99 (65% in
MCF-7 and 70% in MDA-MB-231 cells) and MEK-1, U0126
(102% in MCF-7 and 150% in MDA-MB-231 cells), or PD98059
(110% in MCF-7 and 115% in MDA-MB-231 cells) suppressed
the H/R-induced cell migration in both MCF-7 and MDA-MB-
231 cells. The results showed that the H/R-induced cell migra-
tion is also blocked by anti-uPA antibody in wild type Lck-
transfected MCF-7 (184%) and MDA-MB-231 (205%) cells. The
data are expressed as the mean of three determinations  S.E.
The values were also analyzed by Student’s t test (p  0.001).
These results suggested that EGF receptor and MEK-1 play
crucial roles in H/R-induced Lck-dependent breast cancer cell
migration. These data further demonstrated that p56lck in-
duces EGF receptor phosphorylation and subsequently stimu-
lates MEK-1-ERK1/2-dependent uPA secretion, and all of these
ultimately control the motility of breast cancer cells in the
presence of hypoxia/reoxygenation (Fig. 7).
DISCUSSION
In a recent study (6), we have demonstrated that tyrosine
kinase, p56lck, regulates cell motility and NFB-mediated se-
FIG. 6. As shown in A–C, H/R enhanced p56lck-dependent uPA secretion occurred through EGF receptor and MEK-1-mediated pathways.
MDA-MB-231 cells were transiently transfected with wild type (WT) Lck, mutant Lck F394, Lck F505. or DN Lck. and wild type Lck transfected
cells were treated with inhibitors of Lck, EGF receptor, or MEK-1 and then induced by H/R. The expression of uPA was detected by Western blot
using anti-uPA antibody. Wild type Lck or Lck F505 enhanced the uPA secretion as compared with Lck F394 transfected cells or cells induced by
H/R (A, upper panel, lanes 2–5). A low level of uPA was detected in MDA-MB-231 cells grown under normoxic conditions (lane 1). Lck inhibitors
drastically suppressed the H/R-induced uPA secretion in wild type Lck transfected cells (lanes 6–9). Cells transfected with DN Lck suppressed the
H/R-induced uPA secretion (B, upper panel, lanes 1–3). Inhibitors of EGF receptor or MEK-1 suppressed the H/R-induced uPA secretion in wild
type Lck transfected cells (C, upper panel, lanes 1–7). All of these blots were reprobed with anti-actin antibody (A–C, lower panels). The bands were
quantified by densitometric analysis and normalized with respect to actin, and -fold changes are calculated. The results shown here represent three
experiments exhibiting similar effects. As shown in D and E, EGF receptor, MEK-1, and uPA play crucial roles on H/R-induced Lck-mediated cell
migration. MCF-7 (D) and MDA-MB-231 (E) cells were transiently transfected with wild type Lck, Lck F394, or Lck F505, and wild type Lck
transfected cells were treated with inhibitors of EGF receptor or MEK-1 or with anti-uPA antibody and then induced by H/R. These cells were used
for a migration assay. Cells transfected with either wild type Lck or Lck F505 followed by induction with H/R showed maximum cell migration as
compared with Lck F394 transfected cells or cells induced by H/R alone (D and E), indicating that Tyr-394 of Lck is crucial for H/R-induced cell
migration. Inhibitors of EGF receptor or MEK-1 or anti-uPA antibody suppressed the H/R-induced cell migration in wild type Lck transfected
MCF-7 (D) and MDA-MB-231 (E) cells. The results are expressed as means  S.E. of three determinations. The values were analyzed by Student’s
t test (p  0.001).
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cretion of uPA through tyrosine phosphorylation of IB fol-
lowing hypoxia/reoxygenation (H/R). However, it was not clear
how p56lck in the presence of H/R regulates EGF receptor
phosphorylation and ERK-dependent uPA secretion in breast
cancer cells. Accordingly, we have investigated the role of H/R
on p56lck-dependent EGF receptor phosphorylation in MCF-7
and MDA-MB-231 cells. In this report, we have shown that H/R
induced p56lck phosphorylation and Lck kinase activity in these
cells. H/R also enhanced Lck-dependent EGF receptor phospho-
rylation. Lck induced the phosphorylation of MEK-1 and
ERK1/2 in the presence of H/R, and both inhibitors of EGF
receptors and Lck suppressed these effects, indicating that
H/R-induced MEK-1/ERK1/2 phosphorylation occurred
through Lck and EGF receptor-mediated pathways in breast
cancer cells. Transfection of these cells with wild type Lck or
Lck F505 but not with Lck F394 induced phosphorylations and
activations of EGF receptor followed by MEK-1 and ERK1/2,
suggesting that Tyr-394 of Lck plays important roles in these
processes and Lck is upstream of EGF receptor. H/R also stim-
ulated uPA secretion and cell motility in these cells. Pharma-
cological inhibitors of Lck, EGF receptor, and MEK-1 sup-
pressed the H/R-induced uPA secretion and cell motility.
Similarly, genetic inhibitor of Lck, DN Lck, also inhibited H/R-
induced EGF receptor and ERK1/2 phosphorylations, uPA se-
cretion, and cell motility. These data revealed that p56lck in the
presence of H/R regulates EGF receptor-mediated MEK-1-de-
pendent ERK1/2 phosphorylation, uPA secretion, and cell mo-
tility in breast cancer cells.
Previous results indicated that phosphorylation of Lck at
Tyr-394 by H2O2 is dominant over phosphorylation of Tyr-505
(25). It has been also documented that treatment of cells with
pervanadate or diamide induces Lck phosphorylation at Tyr-
394 and its kinase activity (26). Therefore, it is possible that
these agents may act through a similar mechanism. Our data
reveal that ROS generated by hypoxia/reoxygenation induced
p56lck phosphorylation at Tyr-394 and its kinase activity. In
this study, we have demonstrated that p56lck in the presence of
H/R induced MEK-1 followed by ERK1/2 phosphorylation in
MCF-7 and MDA-MB-231 cells. Both pharmacological (emodin,
pp2, aminogenistein, and damnacanthal) and genetic (DN Lck)
inhibitors of Lck suppressed the H/R-induced MEK-1 phospho-
rylation, indicating that Lck is present upstream of MAPK
kinase.
Epidermal growth factor and its receptor are frequently up-
regulated in different types of human cancers. Earlier reports
have indicated that expression of EGF receptor in colon carci-
noma cells directly correlates with their metastatic potential
(27). In this study, we have shown that H/R enhanced the
Lck-dependent tyrosine phosphorylation of EGF receptor in
breast cancer cells and further demonstrated that EGF recep-
tor inhibitors have no effect on H/R-induced Lck phosphoryla-
tion and its kinase activity, suggesting that Lck is upstream of
EGF receptor. EGF promotes the migration and invasion of a
number of cell types, which has been linked to alternation in
cell-extracellular matrix interactions (28). In this study, we
have also demonstrated that EGF receptor is directly involved
in H/R-induced Lck-mediated breast cancer cell migration. Pre-
vious data also indicated that EGF receptor plays a crucial role
in the activation of MAP kinase pathways, induction of gene
expression (29), and cell motility in different cell types (13, 14).
In our study, we have shown that H/R induced EGF receptor
phosphorylation, which leads to MEK-1-dependent ERK1/2
phosphorylation and cell motility in breast cancer cells. EGF
receptor inhibitors blocked the H/R-induced ERK1/2 phospho-
rylation and cell motility in these cells.
uPA is a serine protease that plays a major role in tumor cell
invasion, malignant progression, and distant metastasis. uPA
is also responsible for regulation of matrix metalloproteinase
activation and cell migration (30, 31). uPA is regulated at
transcriptional level by multiple transcription factor. AP-1
transcription factor duplex plays a major role in the control of
inducible uPA expression through the binding of enhancer re-
gions in the promoter of the uPA gene (17). Therefore, it is
possible that ERK1/2 might regulate the AP-1 transcription
that ultimately controls the uPA secretion and cell migration in
breast cancer cells. In this study, we have detected the level of
uPA in both highly invasive (MDA-MB-231) and low invasive
(MCF-7) breast cancer cells following H/R. H/R-induced uPA
secretion is blocked by both genetic and pharmacological inhib-
itors of Lck and pharmacological inhibitors of MEK-1, suggest-
ing that Lck in the presence of H/R regulates uPA secretion
through MEK-1/ERK1/2-dependent pathways. H/R-induced
Lck-mediated cell migration is also suppressed by uPA anti-
body, indicating that uPA plays an important role in breast
cancer cell motility.
In summary, we have demonstrated for the first time that
H/R induces Lck kinase activity and further indicated that Lck
in the presence of H/R induces the cell migration through
tyrosine phosphorylation of EGF receptor in low and highly
invasive breast cancer cells. H/R also enhanced the phospho-
rylation of MAP kinase kinase and ERK1/2 in these cells. Both
pharmacological and genetic inhibitors of Lck suppressed the
FIG. 7. Molecular mechanism of H/R-induced Lck-dependent
MEK-1-regulated ERK1/2 phosphorylation, uPA secretion, and
cell motility through tyrosine phosphorylation of EGF receptor
in breast cancer cells. H/R induces Lck phosphorylation and its
kinase activity through tyrosine phosphorylation of EGF receptor. Lck
stimulates MEK-1-dependent ERK1/2 phosphorylation (p-ERK), uPA
secretion, and cell motility in the presence of H/R in these cells. Emodin,
pp2, aminogenistein, damnacanthal, AG-99, PD153035, U0126,
PD98059, and DN Lck (K273R) specifically disrupt these signaling
pathways.
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H/R-induced MEK-1/ERK1/2 phosphorylation, suggesting that
Lck plays a significant role in these processes. Lck also induced
uPA secretion and cell motility in the presence of H/R, and
these are suppressed by inhibitors of Lck, EGF receptor, and
MEK-1, indicating that these molecules are involved in uPA
secretion and cell motility. Finally, these data showed that
p56lck in the presence of H/R regulates MEK-1-dependent
ERK1/2 phosphorylation and uPA secretion through tyrosine
phosphorylation of EGF receptor and further demonstrates
that all of these signaling molecules ultimately control the
motility of breast cancer cells. These findings may be useful in
designing novel therapeutic interventions that may disrupt the
redox-regulated p56lck-dependent EGF receptor and MEK-1/
ERK1/2-mediated signaling pathways, resulting in reduction of
uPA secretion and consequent blocking of cell motility and
metastatic spread of breast cancer.
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